Health Condition 1: I350- Nonrheumatic aortic (valve) stenosis
Conditions
Interventions
Intervention1: The Hemodynamx System: The implant is to be implanted in the ascending aorta using a transcatheter
method, intended for decreasing the left ventricle workload in patients with
aortic
Sponsors
Translumina Therapeutics LLP
Eligibility
Inclusion criteria
Inclusion criteria: 1.Assessment and approval by site investigator and sponsor assignee, that patient is eligible candidate for this treatment and study. 2. The patient has been informed of the nature of the study, agrees to its provisions and has provided written informed consent, approved by the applicable Medical Ethics Committee (EC). 3. Greater than 18 years of age 4. Aortic sinotubular junction (STJ) diameter meets the range of 25 to 32 mm, as measured by CT (performed within the past 180 days). 5. Aortic brachiocephalic diameter meets the range of 27 to 35 mm, as measured by CT (performed within the past 180 days). 6. Patient has severe degenerative aortic stenosis with echocardiography derived mean gradient >40mmHg, and/or peak velocity greater than 4.0 m/s, and/or an initial valve area of 7.Patient has symptomatic aortic stenosis as demonstrated by NYHA of II or greater. 8. Patient is within the acceptable surgical risk aortic valve replacement, as assessed by the site investigator and sponsor assignee. 9. Patient has structurally normal cardiac anatomy. 10. Willing and able to comply with all required follow-up evaluation
Exclusion criteria
Exclusion criteria: 1. Patient has a history of a cerebral vascular accident (CVA) or transient ischemic attack (TIA) within the past 12 months. 2. Patient has carotid artery disease requiring intervention. 3. Patient has evidence of a myocardial infarction (MI) within the past 3 months. 4. Patient has hypertrophic cardiomyopathy, based on physician discretion. 5. Patient has a native aortic valve with an abnormal, or eccentric jet, as assessed by echo. 6. Patient has mitral or tricuspid valvular regurgitation of grade III or moderate mitral stenosis, as assessed by echo. 7. Patient has aortic regurgitation more than mild. 8. Patient has rheumatic heart disease 9. Patient had prior CABG operation with ascending aorta grafts. 10. Patient has a pre-existing prosthetic valve or prosthetic ring in any position. 11. Patient refuses blood transfusion or surgical valve replacement. 12. Patient has resting left ventricular ejection fraction (LVEF) less than 30%. 13. Patient has documented, untreated symptomatic coronary artery disease (CAD) requiring revascularization. 14. Patient has severe basal septal hypertrophy, as asses by echo or CT. 15. Patient has had a percutaneous interventional or other invasive cardiac or peripheral procedure 16. Patient has a history of or has active endocarditis. 17. Patient has echocardiographic evidence of intra-cardiac mass, thrombus, or vegetation. 18. Patient has hemodynamic instability (requiring inotropic support or mechanical heart assistance). 19. Patient is in acute pulmonary edema or requiring intravenous diuretic therapy to stabilize heart failure. 20. Patient with significant pulmonary disease 21. Patient has a known hypersensitivity or contraindication to anticoagulant or antiplatelet medication. 22. Patient has renal insufficiency as evidenced by a GFR less than 30 ml per min or end-stage renal disease requiring chronic dialysis. 23. Patientâ??s iliofemoral arteries have severe calcification, tortuosity more than two 90-degree bends, diameter more than 6mm, or subject has had an aorto femoral bypass that preclude safe placement of a 18 French sheath; 24. Patient has blood dyscrasia (leukopenia, acute anemia, thrombocytopenia, bleeding diathesis, or coagulopathy). 25. Patient has a current autoimmune disease that, in the opinion of the Principal Investigator precludes the subject from study participation. 26. Patient with heavily calcified aorta. 27. Patient has a pre-existing endovascular stent graft in the supra- or infrarenal aorta or pre-existing stent grafts in the iliofemoral arteries. 28. Patient has an active peptic ulcer or has had gastrointestinal (GI) bleeding within the past 90 days prior to procedure. 29. Patient has a life expectancy of less than 12 months. 30. Patient has other medical, social or psychological conditions that, in the opinion of the Principal Investigator, preclude the subject from study participation. 31. Patient has a known allergy to contrast media or
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| All-cause mortality Hemodynamic improvement, demonstrated by reduction of the mean aortic pressure gradient by 35%, or effective orifice area improvement of 25%, comparing baseline to 3-month post-procedure measured invasively by a right and left heart catheterization. Timepoint: 30 days 3 months | — |
Secondary
| Measure | Time frame |
|---|---|
| Absence of Device, Investigational Procedure related Serious Adverse Events at 30 days including: Major stroke, Myocardial infarction, Major vascular complication, Major Bleeding, Acute Kidney Injury stage II or III, Study implant deterioration requiring repeat procedure transcatheter or surgical valve replacement Other device-related, or procedure-related SAEsTimepoint: 1 year | — |
Countries
India
Contacts
Public ContactDr Brijesh Mishra
Translumina Therapeutics LLP
Outcome results
None listed